Fly News Breaks for August 11, 2017
Aug 11, 2017 | 09:25 EDT
Craig-Hallum analyst Matt Hewitt said he does not believe the FDA "update" letter regarding potential risks with liquid-filled intragastric balloons will have an adverse impact on future utilization of Apollo Endosurgery's Orbera device and he thinks the selloff related to its publication presents an opportunity for investors. Hewitt keeps a Buy rating and $11 price target on Apollo Endosurgery shares.
News For APEN From the Last 2 Days
There are no results for your query APEN